Indication intelligence, analysis and sector perception

Capricor (CAPR) prepares for a financing with addition of new CFO …

February 23, 2016 12:43pm

… With a more seasoned capital market X- equity research analyst and healthcare investor

CAPR appointed of Leland J. Gershell, M.D., Ph.D. as Chief Financial Officer. Dr. Gershell brings to Capricor over 15 years of experience in the biotech sector, both within the industry and in finance as an equity research analyst and healthcare investor.

Dr. Gershell comes to CAPR from Tonix Pharmaceuticals where he served as its CFO since early 2012. Prior to his corporate career, Dr. Gershell worked in the securities industry as an equity research analyst and covered a variety of therapeutics companies, having started with the biotechnology team at Cowen and Company. He also served as an analyst at Apothecary Capital, a healthcare investment fund. Dr. Gershell has authored numerous articles on the biopharmaceutical industry as well as peer-reviewed scientific reports, and is an inventor on patents for Merck's Zolinza®, the first histone deacetylase (HDAC) inhibitor to receive FDA approval. He earned his M.D. and Ph.D. in Organic Chemistry from Columbia University and his B.A. magna cum laude in Chemistry and Asian Studies from Dartmouth College.

CAPR is down -$0.01 to $2.42 with 405 shares traded, I don't hear a lot of share pricing or volume applause. A falling pichfork?

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.